Loading...
•
Sep 30
Dentsply Sirona Q3 2025 Earnings Report
Dentsply Sirona posted a net loss in Q3 2025 amid sales declines and goodwill impairments, while adjusted earnings remained positive.
Key Takeaways
Dentsply Sirona reported a GAAP net loss of $427 million in Q3 2025 due to $263 million in impairment charges. Revenue declined 5% year-over-year to $904 million, but adjusted EPS was positive at $0.37. The company also introduced a Return-to-Growth strategy to improve performance.
Net sales were $904 million, down 5.0% from Q3 2024
GAAP net loss was $427 million, or ($2.14) per share
Adjusted EPS was $0.37; adjusted EBITDA margin was 18.4%
Cash and cash equivalents rose to $363 million
Dentsply Sirona
Dentsply Sirona
Dentsply Sirona Revenue by Segment
Dentsply Sirona Revenue by Geographic Location
Revenue by Segment
Connected Tech Solutions Revenue
CapyFin.comEssential Dental Solutions Revenue
CapyFin.comOrtho & Implant Solutions Revenue
CapyFin.comWellspect Healthcare Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Dentsply Sirona revised its 2025 outlook downward, projecting full-year revenue between $3.6B and $3.7B and adjusted EPS around $1.60, reflecting continued macro and operational headwinds.
Positive Outlook
- New Return-to-Growth strategy launched to address underperformance
- Leadership changes made to accelerate transformation
- Adjusted EBITDA margin stable at 18.4%
- Cash and equivalents increased to $363 million
- Wellspect Healthcare revenue grew 15.6% year-over-year
Challenges Ahead
- Full-year sales outlook revised down to $3.6–$3.7B
- Adjusted EPS guided to $1.60, down from prior expectations
- U.S. revenue dropped 22.2% year-over-year in Q3
- Orthodontic & Implant revenue fell 15%
- Significant goodwill impairment of $263 million in Q3
Revenue & Expenses
Visualization of income flow from segment revenue to net income